Company news in brief
AstraZeneca-Alexion deal investigatedBritain's competition regulator is reviewing AstraZeneca's US$39 billion buyout of US-based Alexion on concerns it could reduce competition in ...
If you are an active subscriber and the article is not showing, please log out and back in. Free access to articles from 12:00.
Comments
Namibian Sun
No comments have been left on this article